Seeking Alpha

Charles River Labs teams up with Takeda to identify preclinical candidates

|About: Charles River Laborato... (CRL)|By: , SA News Editor

Charles River Laboratories (NYSE:CRL) inks a multiyear agreement with Takeda Pharmaceutical Company (NYSE:TAK) aimed at discovering (and delivering) preclinical candidates across the latter's four core therapeutics areas: oncology, gastroenterology, neuroscience and rare diseases.

Under the terms of the partnership, TAK will pay CRL an upfront fee, up to $50M in development milestones per program, up to $120M in commercial milestones and royalties on net sales.

Try Seeking Alpha PREMIUM for unlimited analysis on CRL